Nexus BioPharma, Inc. is a preclinical stage biotechnology company developing new therapies and intellectual property from our research and development activities for treating obesity and type 2 diabetes.
Effective treatment of obesity is the largest unmet medical need of our time. One billion people in the world are classified as obese, and obesity is the primary cause of the vast majority of diabetes cases. This creates one of the largest potential drug markets that is virtually untapped.
Our innovative approach targets an established metabolic pathway to stimulate weight loss and optimize blood chemistry – including lower blood glucose, cholesterol, insulin, insulin resistance, and triglycerides. In completed pre-clinical trials of the pharmaceutical activation of this pathway, test subjects showed reduced fat mass, a higher rate of energy expenditure and improved blood chemistry. Nexus BioPharma is now advancing to pre-IND trials in preparation for FDA human trials.